BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24328997)

  • 1. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
    Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
    Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
    Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
    Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
    Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
    [No Abstract]   [Full Text] [Related]  

  • 7. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
    Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
    BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
    Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
    J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
    Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
    Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remnant uptake as a postoperative oncologic quality indicator.
    Schneider DF; Ojomo KA; Chen H; Sippel RS
    Thyroid; 2013 Oct; 23(10):1269-76. PubMed ID: 23373869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in differentiated thyroid carcinoma and microcarcinoma.
    Lupoli R; Cacciapuoti M; Tortora A; Barba L; Verde N; Romano F; Vastarella M; Fonderico F; Masone S; Milone M; Lupoli G; Lupoli GA
    Int J Surg; 2014; 12 Suppl 1():S148-51. PubMed ID: 24859408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
    Wang C; Zhao T; Li H; Gao W; Lin Y
    Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
    Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
    Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.